Literature DB >> 28019672

Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies.

Gennaro Pagano1, Flavia Niccolini1, Paolo Fusar-Poli2, Marios Politis1.   

Abstract

Positron emission tomography (PET) is a powerful analytical tool for in vivo molecular imaging of the human brain. Over the past years, a number of PET studies imaging the serotonin transporter (SERT) have been used and provided evidence for the key role of serotonergic pathology in patients with Parkinson's disease (PD). Here, we review the role of SERT in the development of motor and nonmotor complications in patients with PD, and we performed a meta-analysis to identify the patterns of SERT pathology and the relevance to symptoms. Consistent SERT pathology in raphe nuclei, striatum, thalamus, and hypothalamus and associations with aging, PD progression, development of dyskinesias, and cognitive decline were observed. Ann Neurol 2017;81:171-180.
© 2016 American Neurological Association.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28019672     DOI： 10.1002/ana.24859

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  24 in total

Review 1.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

2.  Serotonin, β-amyloid, and cognition in Parkinson disease.

Authors:  Vikas Kotagal; Cathie Spino; Nicolaas I Bohnen; Robert Koeppe; Roger L Albin
Journal:  Ann Neurol       Date:  2018-05-11       Impact factor: 10.422

3.  Imaging SERT Availability in a Rat Model of L-DOPA-Induced Dyskinesia.

Authors:  Michael Walker; Laura Kuebler; Chris Marc Goehring; Bernd J Pichler; Kristina Herfert
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

4.  Estimates of persistent inward currents are reduced in upper limb motor units of older adults.

Authors:  Altamash S Hassan; Melissa E Fajardo; Mark Cummings; Laura Miller McPherson; Francesco Negro; Julius P A Dewald; C J Heckman; Gregory E P Pearcey
Journal:  J Physiol       Date:  2021-09-30       Impact factor: 5.182

5.  Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys.

Authors:  Gunasingh Jeyaraj Masilamoni; Allison Weinkle; Stella M Papa; Yoland Smith
Journal:  Cereb Cortex       Date:  2022-04-20       Impact factor: 4.861

6.  Multiplexed Monitoring of Neurochemicals via Electrografting-Enabled Site-Selective Functionalization of Aptamers on Field-Effect Transistors.

Authors:  Zan Gao; Guangfu Wu; Yang Song; Huijie Li; Yuxuan Zhang; Michael J Schneider; Yingqi Qiang; Jackson Kaszas; Zhengyan Weng; He Sun; Bryan D Huey; Rebecca Y Lai; Yi Zhang
Journal:  Anal Chem       Date:  2022-06-09       Impact factor: 8.008

Review 7.  The role of neuroimaging in Parkinson's disease.

Authors:  Natasha S R Bidesi; Ida Vang Andersen; Albert D Windhorst; Vladimir Shalgunov; Matthias M Herth
Journal:  J Neurochem       Date:  2021-10-03       Impact factor: 5.546

Review 8.  Parkinson disease-associated cognitive impairment.

Authors:  Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub
Journal:  Nat Rev Dis Primers       Date:  2021-07-01       Impact factor: 52.329

Review 9.  Imaging Markers of Progression in Parkinson's Disease.

Authors:  Antonio P Strafella; Nico I Bohnen; Nicola Pavese; David E Vaillancourt; Thilo van Eimeren; Marios Politis; Alessandro Tessitore; Christine Ghadery; Simon Lewis
Journal:  Mov Disord Clin Pract       Date:  2018-10-09

Review 10.  Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment.

Authors:  Yeojin Bang; Juhee Lim; Hyun Jin Choi
Journal:  Arch Pharm Res       Date:  2021-06-19       Impact factor: 4.946
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.